CB8025-31735 PBC

This is a 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA).

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.

Fields marked with an * are required

Newsletter

Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434